Physician profile
Laura J Rayner
NPI 1467695262
$2,199.47
in general payments reported to CMS, 2019-2025
23 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $104 · 2021: $424 · 2022: $457 · 2023: $404 · 2024: $333 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.54 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $311.95 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $234.82 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $206.62 | 2019-2023 | |
| Therapeuticsmd, INC. | $183.67 | 2019-2022 | |
| Pfizer INC. | $182.78 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $124.32 | 2022-2025 | |
| Organon LLC | $120.72 | 2021-2024 | Nexplanon, Nuvaring |
| Agile Therapeutics, INC. | $115.09 | 2021-2024 | Twirla |
| Mylan Pharmaceuticals INC. | $99.55 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.86 | 2020-2023 | |
| Exeltis, USA INC. | $78.79 | 2022-2023 | Slynd |
| Daiichi Sankyo INC. | $63.80 | 2022 | |
| Biogen, INC. | $56.38 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $50.53 | 2021-2024 | Gardasil 9, Gardasil |
| Millicent US INC | $49.13 | 2019-2025 | Intrarosa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $46.21 | 2021-2022 | |
| Avanos Medical | $42.87 | 2019 | |
| Lupin INC. | $30.04 | 2019 | |
| Amag Pharmaceuticals, INC. | $23.61 | 2019 | |
| Sumitomo Pharma America, INC. | $23.36 | 2025 | Myfembree |
| Abbott Laboratories | $22.82 | 2022 | |
| Avion Pharmaceuticals | $20.07 | 2021 | |
| Allergan, INC. | $16.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Rayner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.